Search results for: lung

Manifestations of JIA: JIA-Associated Uveitis, sJIA & Lung Involvement in sJIA

July 16, 2021 • By Jason Liebowitz, MD

JIA can manifest in a variety of ways. Experts discuss the implications of uveitis, systemic disease and lung involvement in sJIA.... [Read More]

Case Report: Rapidly Progressive Interstitial Lung Disease in a 6-Year-Old

April 17, 2021 • By Anusha Vuppala, MD, & Sarwat Umer, MD

Clinically amyopathic dermatomyositis (CADM), a rare subset of dermatomyositis (DM), is an autoimmune disease characterized by cutaneous findings of typical DM without evidence of myositis. Childhood presentation of CADM is rare, and not many studies describe the epidemiology of juvenile CADM.1,2 Although lung disease is rare among patients with juvenile DM, a few reports have… [Read More]

Exploring Leflunomide’s Role in RA with Interstitial Lung Disease

September 11, 2020 • By Rajandeep Paik, MD, FACR

Interstitial lung disease (ILD) is a heterogeneous group of lung parenchymal disorders that share several clinical, radiologic and histopathologic features, and are therefore grouped together.1 ILD can occur in association with most rheumatic connective tissue diseases (CTDs), but patients with systemic sclerosis, polymyositis, dermatomyositis and rheumatoid arthritis have the highest risk of developing ILD.2 A… [Read More]

In the Lungs: Asthma & COPD May Be Early, Independent Risk Factors for RA

June 1, 2020 • By Carina Stanton

Recent research found women with COPD and asthma—even those who have never smoked—are at a higher risk of developing rheumatoid arthritis…... [Read More]

Insights into Interstitial Lung Disease in Rheumatoid Arthritis Patients

October 18, 2019 • By Jason Liebowitz, MD

MADRID—Rheumatoid arthritis (RA) is among the most common autoimmune diseases in the U.S., affecting approximately 1.3 million U.S. adults.1 Although tremendous treatment advances have been made in recent years, one extra-articular manifestation of RA that continues to pose a challenge with regard to detection and management is interstitial lung disease (ILD). At the 2019 European… [Read More]

Transbronchial Lung Cryobiopsy a Valid Diagnostic Option in Interstitial Lung Disease

October 7, 2019 • By Reuters Staff

NEW YORK (Reuters Health)—Transbronchial lung cryobiopsy (TBLC) and surgical lung biopsy (SLB) had a high level of agreement for diagnosing interstitial lung disease in the first comparative study. “These data suggest that TBLC, when done by an experienced proceduralist, is a valid first-line minimally invasive diagnostic tool for patients with interstitial lung disease deemed to… [Read More]

Nintedanib Slows Lung Deterioration in General Fibrosing Interstitial Lung Disease

October 2, 2019 • By Reuters Staff

NEW YORK (Reuters Health)—Nintedanib dramatically slows lung deterioration in patients with progressive fibrosing interstitial lung diseases, according to a new randomized study.1 Nintedanib has already been shown to be effective against idiopathic pulmonary fibrosis (IPF). The new trial, funded by the manufacturer, Boehringer Ingelheim, and presented t the European Respiratory Society International Congress 2019 in… [Read More]

Lessons Learned from Two Scleroderma Lung Studies (Plus a Third That’s Recruiting Sites)

August 16, 2019 • By Elizabeth R. Volkmann, MD, MS, Michael D. Roth, MD, Donald P. Tashkin, MD, Cathie Spino, ScD, & Dinesh Khanna, MD, MS

Historically, the early approach for treating interstitial lung disease (ILD) due to systemic sclerosis (SSc) involved immunosuppressant therapy, primarily with cytotoxic agents.1 Glucocorticoids in combination with another immunosuppressant agent, such as oral azathioprine or cyclophosphamide, were often used to treat patients with severe, progressive SSc-ILD.2 However, direct evidence to support this therapeutic approach was lacking… [Read More]

Results for Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

July 1, 2019 • By Lara C. Pullen, PhD

A study of nintedanib in patients with ILD associated with systemic sclerosis showed the treatment had only limited improvement. Although these patients had a lower rate of decline in forced vital capacity than those on placebo, nintedanib did not result in clinical benefits for other manifestations of systemic sclerosis…... [Read More]

Recent Study Evaluates Nuclear Imaging in Interstitial Lung Disease

May 18, 2019 • By Larry Beresford

A recent proof-of-concept study to evaluate nuclear imaging in interstitial lung disease (ILD) concludes it is feasible to study ILD subtypes using this technology to visualize specific molecular processes of ILD. The process has important potential applications for the development of targeted molecular therapies.1 ILD is an umbrella term for a group of heterogeneous lung… [Read More]